Heidelberg Epignostix, a Heidelberg, Germany-based precision cancer diagnostics startup, raised €4.3M in Seed funding.
The round was led by CARMA FUND I Capital GmbH & Co KG, with participation from High-Tech Gründerfonds, LBBW Venture Capital GmbH and Start-up BW Seed Fonds.
The company intends to use the funds to expand its development efforts for its flagship indication for brain tumor classification.
Heidelberg Epignostix is a healthcare company aiming to transform cancer diagnostics though data science. It has developed novel AI-based bioinformatics algorithms with utility in cancer classification for improved accuracy in cancer diagnosis, prognosis and therapy management. The lead product, the Heidelberg Brain Tumor Classifier, is currently available as a research-use-only resource.
Combining epigenetics with artificial intelligence-powered bioinformatics, the software algorithms enable precise cancer classification of subtypes that are otherwise difficult or impossible to distinguish. The technology is based on DNA methylation which is a pattern of chemical tags on tumor DNA functioning as genomic fingerprints. The algorithm has been applied to more than 150,000 patient samples to date.
FinSMEs
08/07/2024